Amgen has announced plans to reduce the price of its cholesterol drug Repatha by 60% to $5,850 per year, in an effort to improve affordability through lowering patient copays.

The company attributed the price reduction to its participation in the American Heart Association’s (AHA) Value in Healthcare Initiative, and support for the Trump Administration’s aim to lower drug prices.

Repatha is a human monoclonal antibody designed to block proprotein convertase subtilisin/kexin type 9 (PCSK9). It is indicated to treat people having high cholesterol and at risk for heart attacks and strokes.

According to the company, approximately 75% of PCSK9 inhibitor prescriptions for Medicare patients are not filled because of high out-of-pocket costs.

Amgen chairman and CEO Robert Bradway said: “Cardiovascular disease is one of the country’s most significant health challenges, and every 40 seconds someone in America has a heart attack or stroke.

“Repatha can help to address this significant public health issue, but concerns over out-of-pocket costs have proven to be a barrier to its use for too many patients.”

“Repatha can help to address this significant public health issue, but concerns over out-of-pocket costs have proven to be a barrier to its use for too many patients. We want to make sure that every patient who needs Repatha gets Repatha.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Amgen said that the commonly used delivery system SureClick will be available immediately for the lower-priced Repatha. Further, the drug’s Pre-Filled Syringe and Pushtronex delivery systems will be made available over the coming months.

To ensure smooth transition to lower-priced options, Amgen intends to continue offering Repatha at its original list price for certain duration. The company expects to implement the reduced price by the end of 2020 or sooner.

In May this year, Amgen decided not to carry out its price increases planned for July, and will continue the initiative for the rest of the year.

The move was followed by Pfizer in July, when the company announced temporary reversal of its price hikes on 100 products, following Trump’s protests.